Patient-specific melanoma tumor-associated antigens (Neoantigens)

Patient-specific melanoma tumor-associated antigens, commonly known as neoantigens, are novel proteins formed by non-synonymous somatic mutations unique to an individual's tumor (Schumacher & Schreiber, Science, 2015). These antigens are absent from the normal human genome, which allows the immune system to recognize them as non-self without the risk of central tolerance (Ott et al., Nature, 2017). In the context of melanoma, which has one of the highest mutation rates among cancers, these antigens are primary targets for personalized immunotherapy. Therapeutic interventions, such as personalized mRNA or peptide vaccines, utilize these sequences to stimulate the expansion of neoantigen-specific CD4+ and CD8+ T-cells (Sahin et al., Nature, 2017). These activated T-cells then circulate and infiltrate the tumor microenvironment to selectively destroy malignant cells expressing the specific mutations. This personalized approach is often combined with immune checkpoint inhibitors, such as pembrolizumab, to overcome tumor-induced immunosuppression and improve clinical outcomes (Weber et al., Lancet, 2024). Because these targets are exclusive to the tumor, they offer a high degree of safety and reduced risk of systemic autoimmunity compared to shared tumor antigens.

Other names

NeoantigensTumor-specific antigensTSAsPersonalized melanoma antigensMutated self-antigensIndividualized tumor-associated antigens

Induction of a de novo, patient-specific T-cell response by delivering synthetic mRNA or peptides encoding unique tumor mutations, which are then processed and presented on MHC molecules to activate cytotoxic T lymphocytes (Schumacher & Schreiber, Science, 2015; Sahin et al., Nature, 2017).